MPC Therapeutics closes CHF 1.5M seed-funding round

MPC Therapeutics, a biotechnology spin-off of UNIGE focused on metabolism and cellular rejuvenation, announced on January 10th, 2023 the completion of its CHF 1.5M seed-funding round to improve CAR-T cancer therapies.

Funds will serve to advance MPC Therapeutics's proprietary small molecule towards clinical trials and open new therapeutic applications.

Read full press release here.